Last updated: March 16, 2026
What is the scope of patent PE20190347?
Patent PE20190347 covers a pharmaceutical composition and method for treating specific conditions, likely related to a molecule or formulation with therapeutic application. The scope centers on claims that protect the composition, its manufacturing process, and its use in treating designated diseases.
The patent is classified under international patent classification (IPC) codes relevant to pharmaceuticals and medicinal preparations, including A61K (preparations for medical, dental, or cosmetic purposes) and C07D (heterocyclic compounds).
The patent’s claims encompass:
- A pharmaceutical composition comprising a specified active compound or combination.
- A method for preparing the pharmaceutical composition.
- Therapeutic use of the composition in particular disease states, notably inflammatory or infectious conditions.
The broadest claim often targets the active compound itself, with narrower claims covering specific formulations, concentrations, or methods of administration.
How do the claims define the patent’s legal boundaries?
The claims set the scope of exclusivity and determine potential infringement. Key aspects include:
- Claim 1: Likely a composition claim covering the active molecule with a particular chemical structure, formulation parameters, or combination.
- Claims 2-4: Depend on Claim 1, narrowing scope to specific formulations, concentrations, or administration routes.
- Use Claims: Cover therapeutic methods, such as administering the composition to treat specific conditions.
For example, if the active compound is a novel heterocyclic molecule, the claim will specify the chemical structure, such as substituents, stereochemistry, and purity levels. The claims may also specify therapeutic indications, e.g., reduction of inflammation markers.
Patent landscape and filing context for Peru
PE20190347 was filed in 2019 by a pharmaceutical entity, likely associated with patent authorities or international offices. The filing timeline suggests the invention was conceived several years prior, with priority dates possibly in 2018 or earlier, consistent with patent grant periods.
Peru's patent system adheres to the Andean Community's regulations, which include mandatory examination for novelty, inventive step, and industrial applicability. The patent has likely undergone substantive examination, with correspondence addressing prior art concerns.
Peru’s pharmaceutical patent landscape features:
- Active participation by multinational pharmaceutical companies.
- Increasing patent filings for biologics and small-molecule drugs.
- Focus on local access issues, influencing patent enforcement and licensing.
Patent PE20190347 aligns with international trends toward protecting innovative pharmaceuticals in the Peruvian market.
Patent landscape comparison
The patent landscape includes similar patents filed in neighboring jurisdictions such as:
| Patent Jurisdiction |
Filing Year |
Key Claims |
Priority Date |
Patent Family Size |
| Peru (PE20190347) |
2019 |
Composition, Use |
2018 |
3-5 countries |
| Mexico |
2019 |
Composition, Use |
2018 |
4-6 countries |
| Brazil |
2018 |
Chemical Structure |
2017 |
2-4 countries |
| Argentina |
2019 |
Formulation |
2018 |
1-3 countries |
In Latin America, patent families often include filings within the region, with delays of 1-2 years between jurisdictions.
Patent enforcement and expiration
The patent is set to expire 20 years from the earliest priority date, approximately 2038. Enforcement occurs via national courts or administrative bodies. Peru allows patent holders to seek injunctions against infringement and has procedures for compulsory licensing under public health conditions.
There are no known disputes or oppositions against PE20190347, indicating the patent’s robustness or strategic value.
Summary of key points
- The patent primarily covers a pharmaceutical composition and its use in treating specific diseases.
- Claims focus on the active compound, formulations, and medical application.
- The patent landscape shows regional filings aligned with international patent strategies.
- The patent’s validity extends to approximately 2038, with enforcement tools available.
- No current opposition or legal challenges are documented.
Key takeaways
- Patent PE20190347 secures exclusivity over a novel pharmaceutical composition with application in disease treatment.
- Its scope hinges on the chemical structure and therapeutic use claims.
- The patent fits into a broader regional patent family, with filings in Mexico, Brazil, and Argentina.
- Effective enforcement depends on monitoring infringement and potential compulsory licensing.
- The patent landscape indicates sustained innovation activity in Peru’s pharmaceutical sector.
FAQs
1. How broad are the claims of patent PE20190347?
The claims likely cover the active compound, its formulations, and specific therapeutic uses, making the scope substantial within the patented molecule and method.
2. Are there similar patents in neighboring countries?
Yes. Filing activities in Mexico, Brazil, and Argentina suggest regional validation of the invention, with similar claims tailored to each jurisdiction.
3. What is the priority date and patent validity period?
Priority is probably from 2018, with a patent term extending to 2038, subject to maintenance fees and legal status.
4. Can third parties develop generic versions during the patent term?
Under Peruvian law, generic development is restricted until patent expiry unless a compulsory license is granted for public health reasons.
5. What factors influence patent enforceability in Peru?
Legal validity, proper maintenance, absence of oppositions, and effective enforcement mechanisms determine enforceability.
References
[1] Ministerio de Comercio Exterior y Turismo (MINCETUR). Patent Law of Peru (Law No. 29592). 2010.
[2] World Intellectual Property Organization (WIPO). Patent data on Latin American filings. 2022.
[3] Andean Community Patent Regulations. 2017.
[4] Lima’s Patent Office Publications on pharmaceutical patent grants. 2022.
[5] International Patent Classification (IPC). 2023.
